For a limited time, The Motley Fool Australia is giving away an urgent new investment report outlining our 5 favourite stocks for investors over 50. Each company boasts strong growth prospects over the next 3 to 5 years, and most importantly each pays a generous (and fully franked) dividend! So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered!
Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
About Alterity Therapeutics Ltd (ASX: ATH)
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).